RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells
- PMID: 24704199
- DOI: 10.1016/j.ejpb.2014.03.016
RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells
Abstract
Background: To facilitate selective drug delivery to hepsin (Hpn)-expressing cancer cells, the RIPL peptide (IPLVVPLRRRRRRRRC; 16mer; 2.1 kDa) was synthesized as a novel cell penetrating/homing peptide (CPHP) and conjugated to a liposomal carrier.
Methods: RIPL peptide-conjugated liposomes (RIPL-Lipo) were prepared by conjugating RIPL peptides to maleimide-derivatized liposomal vesicles via the thiol-maleimide reaction. Vesicle size and zeta potential were examined using a Zetasizer. Intracellular uptake specificity of the RIPL peptide, or RIPL-Lipo, was assessed by measuring mean fluorescence intensity (MFI) after treatment with a fluorescent marker in various cell lines: SK-OV-3, MCF-7, and LNCaP for Hpn(+); DU145, PC3, and HaCaT for Hpn(-). FITC-dextran was used as a model compound. Selective translocational behavior of RIPL-Lipo to LNCaP cells was visualized by fluorescence microscopy and confocal laser scanning microscopy. Cytotoxicities of the RIPL peptide and RIPL-Lipo were evaluated by WST-1 assay.
Results: RIPL peptides exhibited significant Hpn-selectivity. RIPL-Lipo systems were of positively charged nanodispersion (165 nm in average; 6-24 mV depending on RIPL conjugation ratio). RIPL-Lipo with the conjugation of 2300 peptide molecules revealed the greatest MFI in all cell lines tested. Cellular uptake of RIPL-Lipo increased by 20- to 70-fold in Hpn(+) cells, and 5- to 7-fold in Hpn(-) cells, compared to the uptake of FITC-dextran. Cytosolic internalization of RIPL-Lipo was time-dependent: bound instantly; internalized within 30 min; distributed throughout the cytoplasm after 1 h. Cytotoxicities of RIPL peptide (up to 50 μM) and RIPL-Lipo (up to 10%) were minor (cell viability >90%) in LNCaP and HaCaT cells.
Conclusion: By employing a novel CPHP, the RIPL-Lipo system was successfully developed for Hpn-specific drug delivery.
Keywords: Cell penetrating/homing peptide; Hepsin; IPL; Intracellular delivery; Liposome; Polyarginine; Targeting.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells.Int J Nanomedicine. 2018 Jun 1;13:3263-3278. doi: 10.2147/IJN.S166021. eCollection 2018. Int J Nanomedicine. 2018. PMID: 29910614 Free PMC article.
-
Docetaxel-loaded RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes: Drug release, cytotoxicity, and antitumor efficacy.Int J Pharm. 2017 May 15;523(1):229-237. doi: 10.1016/j.ijpharm.2017.03.045. Epub 2017 Mar 21. Int J Pharm. 2017. PMID: 28341149
-
Surface-Modification of RIPL Peptide-Conjugated Liposomes to Achieve Steric Stabilization and pH Sensitivity.J Nanosci Nanotechnol. 2017 Feb;17(2):1008-17. doi: 10.1166/jnn.2017.12670. J Nanosci Nanotechnol. 2017. PMID: 29671978
-
Strategies for cytosolic delivery of liposomal macromolecules.Int J Pharm. 2005 Jul 25;298(2):305-9. doi: 10.1016/j.ijpharm.2005.02.040. Int J Pharm. 2005. PMID: 15941633 Review.
-
Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer.Anticancer Agents Med Chem. 2016;16(7):816-31. doi: 10.2174/1871520616666151116121821. Anticancer Agents Med Chem. 2016. PMID: 26567624 Review.
Cited by
-
Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes.Semin Cell Dev Biol. 2015 Apr;40:41-51. doi: 10.1016/j.semcdb.2015.02.010. Epub 2015 Feb 23. Semin Cell Dev Biol. 2015. PMID: 25721812 Free PMC article. Review.
-
Lipid-Based Nanotechnology: Liposome.Pharmaceutics. 2023 Dec 26;16(1):34. doi: 10.3390/pharmaceutics16010034. Pharmaceutics. 2023. PMID: 38258045 Free PMC article. Review.
-
pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation.Int J Nanomedicine. 2018 Oct 23;13:6661-6675. doi: 10.2147/IJN.S184355. eCollection 2018. Int J Nanomedicine. 2018. PMID: 30425481 Free PMC article.
-
Surface density of polyarginine influence the size, zeta potential, cellular uptake and tissue distribution of the nanostructured lipid carrier.Drug Deliv. 2017 Nov;24(1):519-526. doi: 10.1080/10717544.2016.1269849. Drug Deliv. 2017. PMID: 28181841 Free PMC article.
-
Sterically Stabilized RIPL Peptide-Conjugated Nanostructured Lipid Carriers: Characterization, Cellular Uptake, Cytotoxicity, and Biodistribution.Pharmaceutics. 2018 Oct 23;10(4):199. doi: 10.3390/pharmaceutics10040199. Pharmaceutics. 2018. PMID: 30360549 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources